Inflammatory meditated mechanisms of cisplatin resistance in non-small cell lung cancer
| Data(s) |
2016
|
|---|---|
| Resumo |
The majority of non-small cell lung cancer (NSCLC) patients present with advanced stage disease, where chemotherapy is usually the most common treatment option. While somewhat effective, patients treated with cisplatin-based chemotherapy will eventually develop resistance. Multiple pathways have been implicated in chemo-resistance, however the critical underlying mechanisms have yet to be elucidated. The aim of this project is to determine the role of inflammatory mediators in cisplatin resistance. |
| Identificador | |
| Publicador |
Elsevier |
| Relação |
DOI:10.1016/S1556-0864(16)30181-2 O'Byrne, K., Ryan, S-L, Heavey, S., Umezawa, K., Barr, M.P., Gray, S.G., Davies, A., Richard, D., Gately, K., & Baird, A.-M. (2016) Inflammatory meditated mechanisms of cisplatin resistance in non-small cell lung cancer. In European Lung Cancer Conference (ELCC 2016), 13 - 16 April 2016, Geneva, Switzerland. |
| Fonte |
School of Biomedical Sciences; Faculty of Health; Institute of Health and Biomedical Innovation |
| Tipo |
Conference Item |
